INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART) Files An 8-K Entry into a Material Definitive Agreement
ITEM1.01. ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On March31, 2017, Integra LifeSciences Holdings Corporation (the
Company) entered into an amendment (the Amendment) to that
certain Fourth Amended and Restated Credit Agreement, dated as of
December7, 2016 (as so amended by the Amendment, the Credit
Agreement) among the Company, a syndicate of lending banks, and
Bank of America, N.A., as Administrative Agent.
The Amendment establishes a $700 million delayed draw term loan A
facility, resulting in credit facilities having an aggregate
principal amount of up to $2.2 billion being available to the
Company. Subject to the satisfaction of customary conditions, the
delayed draw term loan will be borrowed in connection with, and
the proceeds of which will be used (together with borrowings
under our existing revolving credit facility) to consummate and
finance, the acquisition contemplated by the Asset Purchase
Agreement dated February14, 2017 between the Company and DuPuy
Synthes, Inc., a Delaware corporation. In connection with the
Amendment, we expect that the financing commitments from Bank of
America, N.A. and JPMorgan Chase Bank, N.A. issued to us in
February will be terminated.
A copy of the Amendment is attached as Exhibit 4.1 to this
Current Report on Form 8-K and is incorporated into this
Item1.01. The foregoing summary does not purport to be complete
and is qualified in its entirety by reference to the full text of
the Amendment and of the Credit Agreement.
The press release issued by the Company announcing its entering
into the Amendment is attached as Exhibit 99.1 to this Current
Report on Form 8-K.
ITEM9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) EXHIBITS
| 4.1 |
Amendment, dated as of March31, 2017, to that Fourth Amended and Restated Credit Agreement, among Integra LifeSciences Holdings Corporation a syndicate of lending banks, and Bank of America, N.A., as Administrative Agent. |
|
| 99.1 | Press Release issued April4, 2017. |
About INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART)
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing and marketing of surgical implants and medical instruments. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery. Its segments include Specialty Surgical Solutions, which offers products, including specialty surgical instrumentation for a range of specialties. Its product category includes products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care, including product portfolios used in neurosurgery operation suites and critical care units, and Orthopedics and Tissue Technologies, which offers products of a combination of differentiated regenerative technology products for soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement hardware products for both upper extremities and lower extremities. INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART) Recent Trading Information
INTEGRA LIFESCIENCES HOLDINGS CORPORATION (NASDAQ:IART) closed its last trading session down -0.56 at 41.45 with 472,490 shares trading hands.